LeMaitre Vascular (NASDAQ:LMAT) Coverage Initiated at Wells Fargo & Company

Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular (NASDAQ:LMATFree Report) in a research note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage issued an equal weight rating and a $95.00 price target on the medical instruments supplier’s stock.

Several other brokerages have also recently commented on LMAT. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Oppenheimer restated an “outperform” rating and set a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Finally, Barrington Research upped their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $94.63.

View Our Latest Report on LeMaitre Vascular

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $96.99 on Thursday. LeMaitre Vascular has a 52 week low of $59.04 and a 52 week high of $109.58. The firm’s 50-day simple moving average is $96.10 and its 200 day simple moving average is $93.47. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of 53.00, a P/E/G ratio of 2.19 and a beta of 0.96.

Hedge Funds Weigh In On LeMaitre Vascular

Hedge funds and other institutional investors have recently modified their holdings of the business. Smartleaf Asset Management LLC lifted its position in shares of LeMaitre Vascular by 234.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC raised its stake in LeMaitre Vascular by 38.5% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 117 shares in the last quarter. NBC Securities Inc. raised its stake in LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 183 shares in the last quarter. KBC Group NV lifted its holdings in shares of LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after acquiring an additional 410 shares during the last quarter. Finally, Huntington National Bank boosted its stake in shares of LeMaitre Vascular by 64.9% in the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier’s stock valued at $107,000 after purchasing an additional 455 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

(Get Free Report)

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Featured Articles

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.